ABSTRACT
Importance Chronic pain is a major public-health problem in the US. The COVID-19 pandemic led to widespread disruptions in the US. It remains unclear, however, how medical and societal changes during this period affected national chronic pain prevalence, a key dimension of population health.
Objective To determine prevalence of chronic pain (CP) and high-impact chronic pain (HICP) before, during, and after COVID-19 pandemic and explore reasons driving the trends
Methods We use data from the 2019, 2021, and 2023 National Health Interview Survey (NHIS), a multi-wave cross-sectional survey. Nationally representative sample of non-institutionalized civilian US population age 18 and older (n=88,469). Year of interview is the exposure. All regression models control for age and sex; some models include additional 19 covariates (demographics, socioeconomic status, health behaviors, health conditions, mental health, and health insurance type); analyses also explore the role of COVID and long COVID. Primary outcomes were the prevalence of CP and HICP measured via widely-used validated measures. CP was based on the question “In the past 3 months, how often did you have pain? Would you say never, some days, most days, or every day?”; CP is defined as pain on most days or every day. HICP was defined as chronic pain that limited life or work activities on most days or every day (versus never or some days).
Results Chronic pain prevalence was 20.6% (19.9-21.2%) in 2019, 20.9% (20.3-21.6%) in 2021, and 24.3% (23.7-25.0%) in 2023. HICP also increased from 7.5% (7.1-7.8%) in 2019, to 8.5% (8.1-8.9%) in 2023, after a decline to 6.9% (6.6-7.3%) in 2021. The 2023 increases occurred in all examined body sites except for dental pain. COVID and long COVID had a modest role in the population-wide pain increases, the causes of which remain unclear.
Conclusions and Relevance Pain among US adults was high before the pandemic but surged dramatically since. In 2023, an unprecedented 60 million Americans had chronic pain and 21 million had high-impact chronic pain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this analysis was supported by the Social Sciences and Humanities Research Council of Canada (SSHRC) Insight Grant and by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG065351. The content is solely the responsibility of the authors and does not necessarily represent the official views of the SSHRC or the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used in the present study are available publicly online at https://nhis.ipums.org/nhis/. All Stata code is available on request to the authors.
